Literature DB >> 31726889

Mucinous ovarian cancer: current therapeutic targets, preclinical progress, and experimental drugs.

Melita Moioli1,2, Fabio Barra1,2, Mattia Maramai1,2, Mario Valenzano Menada1,2, Valerio Gaetano Vellone3, Sergio Costantini1,2, Simone Ferrero1,2.   

Abstract

Entities:  

Keywords:  KRAS; Mucinous epithelial ovarian cancer; chemoresistance; genetic mutations; molecular pathways; targeted therapy

Mesh：

Substances：

Year:  2019        PMID： 31726889     DOI： 10.1080/13543784.2019.1693999

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN： 1354-3784            Impact factor:   6.206


× No keyword cloud information.
  2 in total

1.  Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypes.

Authors:  Shan Zhu; Chunliu Zhang; Dongyan Cao; Jing Bai; Shuangni Yu; Jie Chen; Jing Wang; Tong Ren; Jiaxin Yang; Mei Yu; Xiao Xiao; Yuhua Gong; Yanfang Guan; Peiling Li; Ying Yue; Rutie Yin; Yongjun Wang; Ruifang An; Ge Lou; Jianlin Yuan; Guonan Zhang; Xuefeng Xia; Ling Yang; Yang Xiang
Journal:  Oncogene       Date:  2022-04-25       Impact factor: 9.867

2.  Histological Characteristics and Early-Stage Diagnosis Are Associated With Better Survival in Young Patients With Epithelial Ovarian Cancer: A Retrospective Analysis Based on Surveillance Epidemiology and End Results Database.

Authors:  Yue Huang; Xiu Ming; Bingjie Li; Zhengyu Li
Journal:  Front Oncol       Date:  2020-12-23       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.